HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

EBS

Emergent Biosolutions Inc

Last Close
May 30 • 04:00PM ET
6.32
Dollar change
-0.14
Percentage change
-2.17 		%
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NYSE
Peers: MRNA SNY NVAX DVAX INBX OCGN VXRT ADMA XERS HEPA
 | Held by: AVUV VTI XBI PRFZ VXF IBB DFAT SCHA FNDA DFAS
Index- P/E- EPS (ttm)-2.71 Insider Own4.37% Shs Outstand54.50M Perf Week-2.77%
Market Cap343.04M Forward P/E5.06 EPS next Y1.25 Insider Trans0.30% Shs Float51.91M Perf Month18.35%
Income-131.60M PEG- EPS next Q-0.10 Inst Own66.76% Short Float15.24% Perf Quarter-15.51%
Sales965.40M P/S0.36 EPS this Y469.57% Inst Trans4.33% Short Ratio5.91 Perf Half Y-35.84%
Book/sh10.14 P/B0.62 EPS next Y47.06% ROA-8.15% Short Interest7.91M Perf Year33.90%
Cash/sh2.82 P/C2.25 EPS next 5Y- ROE-21.63% 52W Range4.02 - 15.10 Perf YTD-33.89%
Dividend Est.- P/FCF3.63 EPS past 5Y- ROI-10.76% 52W High-58.15% Beta2.11
Dividend TTM- Quick Ratio3.51 Sales past 5Y-1.15% Gross Margin29.20% 52W Low57.21% ATR (14)0.44
Dividend Ex-Date- Current Ratio6.32 EPS Y/Y TTM76.88% Oper. Margin-5.14% RSI (14)55.78 Volatility2.18% 8.90%
Employees900 Debt/Eq1.22 Sales Y/Y TTM-18.56% Profit Margin-13.63% Recom2.33 Target Price13.50
Option/ShortYes / Yes LT Debt/Eq1.21 EPS Q/Q588.34% Payout- Rel Volume0.67 Prev Close6.46
Sales Surprise1.46% EPS Surprise61.36% Sales Q/Q-26.03% EarningsMay 07 AMC Avg Volume1.34M Price6.32
SMA205.58% SMA5017.89% SMA200-20.19% Trades Volume902,097 Change-2.17%
Date Action Analyst Rating Change Price Target Change
Dec-30-24Initiated H.C. Wainwright Buy $15
Aug-22-24Initiated Rodman & Renshaw Buy $16
Mar-07-24Upgrade The Benchmark Company Hold → Buy $5
Nov-20-23Resumed JP Morgan Underweight
Aug-29-23Downgrade The Benchmark Company Buy → Hold
Apr-10-23Upgrade The Benchmark Company Hold → Buy $22
Mar-17-23Downgrade JP Morgan Neutral → Underweight $23 → $9
Nov-10-22Downgrade The Benchmark Company Buy → Hold
Apr-29-22Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22Upgrade The Benchmark Company Hold → Buy $77
Show Previous Ratings
May-29-25 09:55AM
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
(Zacks)
May-19-25 09:43AM
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions
(Zacks)
May-16-25 10:52AM
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
(Zacks) +20.95%
May-14-25 07:32AM
Emergent BioSolutions to Participate in Upcoming Investor Conferences
(GlobeNewswire)
May-08-25 09:53AM
Q1 2025 Emergent BioSolutions Inc Earnings Call
(Thomson Reuters StreetEvents) +34.18%
03:33AM Loading…
03:33AM
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ...
(GuruFocus.com)
May-07-25 10:03PM
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress
(Seeking Alpha)
10:01PM
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
(Seeking Alpha)
05:35PM
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
(Zacks)
04:32PM
Emergent Biosolutions: Q1 Earnings Snapshot
(Associated Press Finance)
04:05PM
Emergent BioSolutions Reports First Quarter 2025 Financial Results
(GlobeNewswire)
May-01-25 05:07PM
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
(GlobeNewswire) -7.87%
Apr-22-25 08:00AM
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
(GlobeNewswire)
Apr-10-25 09:52AM
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
(Zacks) -9.17%
Apr-09-25 08:45AM
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
(Zacks) +9.58%
12:24AM Loading…
Apr-08-25 12:24AM
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
(Seeking Alpha)
Mar-31-25 08:00AM
Emergent BioSolutions Announces Stock Repurchase Program
(GlobeNewswire)
Mar-26-25 10:32AM
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
(SeekingAlpha) -6.00%
Mar-20-25 04:30PM
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
(GlobeNewswire)
08:30AM
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues
(SeekingAlpha)
08:06AM
Hikma announces Health Canada approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg
(GlobeNewswire)
Mar-19-25 05:01PM
Emergent BioSolutions closes sale of Bayview facility to Syngene
(SeekingAlpha)
04:30PM
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
(GlobeNewswire)
Mar-18-25 08:00AM
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
(GlobeNewswire)
Mar-13-25 11:00AM
Emergent signs financial investment agreement with Swiss Rockets
(Pharmaceutical Technology) -10.41%
08:29AM
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
(GlobeNewswire)
Mar-12-25 08:00AM
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
(GlobeNewswire) +11.21%
Mar-10-25 09:14AM
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
(GlobeNewswire)
Mar-04-25 06:59AM
Q4 2024 Emergent BioSolutions Inc Earnings Call
(Thomson Reuters StreetEvents) -6.44%
02:45AM
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
(Motley Fool)
02:05AM Loading…
02:05AM
Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ...
(GuruFocus.com)
Mar-03-25 05:40PM
Emergent Biosolutions (EBS) Q4 Earnings Top Estimates
(Zacks) -8.69%
04:45PM
Emergent Biosolutions: Q4 Earnings Snapshot
(Associated Press Finance)
04:23PM
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Feb-18-25 08:55AM
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
(GlobeNewswire) -14.20%
Feb-07-25 08:06AM
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
(GlobeNewswire)
Jan-23-25 09:01AM
Emergent seeking to reverse fortunes and become a major overdose treatment player
(Pharmaceutical Technology) +5.61%
Jan-16-25 08:00AM
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
(GlobeNewswire)
Jan-14-25 07:30AM
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
(GlobeNewswire)
Jan-13-25 09:27AM
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga (ansuvimab-zykl) Treatment for Ebola
(GlobeNewswire)
Jan-08-25 07:45AM
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
(GlobeNewswire)
07:30AM
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax (Anthrax Vaccine Adsorbed)
(GlobeNewswire)
Dec-30-24 05:26PM
Why Emergent BioSolutions Stock Blasted Higher Today
(Motley Fool) +11.85%
Dec-16-24 08:00AM
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted)
(GlobeNewswire)
Dec-03-24 06:47PM
Why Emergent BioSciences Stock Plummeted Today
(Motley Fool) -5.59%
Nov-08-24 10:04AM
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com) +7.00%
Nov-07-24 02:06PM
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
(Benzinga) +19.57%
01:15AM
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
(Motley Fool)
Nov-06-24 06:20PM
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
(Zacks)
05:17PM
Emergent Biosolutions: Q3 Earnings Snapshot
(Associated Press Finance)
04:49PM
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
(GlobeNewswire)
04:05PM
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
(GlobeNewswire)
Nov-04-24 07:30AM
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
(GlobeNewswire)
Oct-23-24 07:30AM
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
(GlobeNewswire) -5.20%
Oct-11-24 12:33PM
Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024
(Insider Monkey)
Oct-09-24 05:09PM
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...
(GuruFocus.com) -5.38%
11:09AM
Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says
(Pharmaceutical Technology)
Oct-08-24 05:32PM
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN Nasal Spray to Help Combat the Opioid Epidemic
(GlobeNewswire)
Oct-02-24 07:30AM
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
(GlobeNewswire) +8.50%
Sep-26-24 08:05AM
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA (brincidofovir) to Support National Preparedness Efforts
(GlobeNewswire) +22.56%
Sep-25-24 07:07AM
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
(GlobeNewswire)
Sep-13-24 06:45AM
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
(GlobeNewswire)
Sep-12-24 08:30AM
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola
(GlobeNewswire)
01:27AM
BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc.
(GuruFocus.com)
Sep-04-24 05:51PM
OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing
(GlobeNewswire)
08:00AM
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
(GlobeNewswire)
Sep-03-24 07:08AM
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
(GlobeNewswire) -11.07%
Aug-30-24 09:55AM
Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine
(Barrons.com) -6.73%
08:33AM
This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval
(Investor's Business Daily)
08:33AM
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine
(Investor's Business Daily)
08:16AM
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
(GlobeNewswire)
04:32AM
Emergent gains FDA approval for ACAM2000 vaccine for Mpox
(Pharmaceutical Technology)
Aug-29-24 06:53PM
Emergent BioSolutions' ACAM2000 , (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
(GlobeNewswire)
Aug-21-24 11:14AM
Emergent BioSolutions finalises manufacturing site sale to Bora Pharmaceuticals
(Pharmaceutical Technology) +8.82%
Aug-20-24 12:03PM
Emergent joins mpox fight with 50,000 vaccine dose donation to Africa
(Pharmaceutical Technology) -20.33%
11:30AM
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
(GlobeNewswire)
Aug-19-24 05:16PM
WHO declares mpox a public health emergency as variant emerges
(Yahoo Finance Video) +12.66%
05:10PM
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
(GlobeNewswire)
Aug-16-24 04:14PM
Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval
(Bloomberg) +24.02%
12:51PM
Why Emergent BioSolutions Stock Is Skyrocketing Today
(Motley Fool)
09:52AM
Mpox Vaccine Makers Stock Soars After Fresh WHO Warning
(Barrons.com)
Aug-07-24 02:45AM
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
(Motley Fool) -41.99%
Aug-06-24 05:14PM
Emergent Biosolutions: Q2 Earnings Snapshot
(Associated Press Finance)
05:01PM
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
(GlobeNewswire)
08:00AM
Emergent BioSolutions Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
(GlobeNewswire)
Jul-31-24 09:06AM
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL (Reactive Skin Decontamination Lotion) kit for $75 million
(GlobeNewswire) +7.08%
08:53AM
Emergent BioSolutions Completes Sale of RSDL (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
(GlobeNewswire)
Jul-25-24 01:20PM
The stock markets cruel summer is about to get much worse
(MarketWatch)
Jul-24-24 07:30AM
Emergent BioSolutions Launches Opioid Emergency Preparedness 'Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
(GlobeNewswire) +10.57%
Jul-23-24 08:27AM
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
(GlobeNewswire) +8.99%
Jul-22-24 08:00AM
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada
(GlobeNewswire)
Jul-09-24 07:30AM
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
(GlobeNewswire) +7.26%
Jul-03-24 10:13AM
Emergent scores US medical countermeasure contracts worth over $250m
(Pharmaceutical Technology)
Jul-02-24 09:43AM
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
(GlobeNewswire) +6.09%
08:13AM
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
(GlobeNewswire)
Jun-24-24 06:35AM
7 Top Stocks Under $10: June 2024 Edition
(InvestorPlace)
Jun-21-24 06:53AM
Emergent to sell US sterile manufacturing facility to Bora
(Pharmaceutical Technology)
Jun-20-24 07:00AM
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
(GlobeNewswire) +6.77%
Jun-06-24 09:02AM
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
(GlobeNewswire) -6.15%
May-21-24 07:00AM
7 Stocks to Buy Immediately Following Strong Earnings
(InvestorPlace) -10.69%
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Katkin KeithDirectorMay 23 '25Sale6.307,84449,41786,431May 28 04:08 PM
KEITH KATKINDirectorMay 23 '25Proposed Sale6.307,84449,409May 23 04:04 PM
PAPA JOSEPH CPresident and CEOMay 13 '25Buy5.8360,000349,800342,500May 15 04:02 PM
Fowler Neal FranklinDirectorMar 12 '25Sale5.8335,000204,050101,100Mar 12 06:13 PM
Zoon Kathryn CDirectorMar 12 '25Sale5.7310,00057,30044,482Mar 12 06:13 PM
Fowler Neal FranklinDirectorMar 12 '25Proposed Sale5.8335,000204,005Mar 12 05:34 PM
Zoon Kathryn CDirectorMar 12 '25Proposed Sale5.7310,00057,300Mar 12 05:23 PM
DeGolyer Donald WDirectorNov 12 '24Sale10.9125,000272,750111,100Nov 14 04:18 PM
White Marvin LDirectorNov 11 '24Sale11.9714,287171,01554,092Nov 13 04:04 PM
DeGolyer Donald WDirectorNov 12 '24Proposed Sale11.7725,000294,250Nov 12 05:16 PM
White Marvin LDirectorNov 11 '24Proposed Sale11.7714,287168,158Nov 12 10:34 AM
Zoon Kathryn CDirectorJun 04 '24Sale6.1110,00061,10054,482Jun 06 04:16 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

SNDX

Syndax Pharmaceuticals Inc

Last Close
May 30 • 04:00PM ET
10.54
Dollar change
-0.08
Percentage change
-0.75 		%
Healthcare • Biotechnology • USA • NASD
SNDX Syndax Pharmaceuticals Inc daily Stock Chart
Peers: LLY MRK PFE JNJ BMY AMGN GILD REGN VRTX BMRN
 | Held by: VTI IWM XBI VXF IWO VTWO IBB SCHA VHT LABU
IndexRUT P/E- EPS (ttm)-3.87 Insider Own4.16% Shs Outstand86.05M Perf Week-2.50%
Market Cap906.94M Forward P/E- EPS next Y-2.70 Insider Trans-0.08% Shs Float82.47M Perf Month-25.51%
Income-331.20M PEG- EPS next Q-1.00 Inst Own115.48% Short Float26.35% Perf Quarter-32.61%
Sales43.72M P/S20.74 EPS this Y-1.37% Inst Trans3.50% Short Ratio9.47 Perf Half Y-37.00%
Book/sh2.50 P/B4.22 EPS next Y28.49% ROA-55.96% Short Interest21.73M Perf Year-47.51%
Cash/sh5.95 P/C1.77 EPS next 5Y27.48% ROE-93.70% 52W Range8.58 - 25.07 Perf YTD-20.27%
Dividend Est.- P/FCF- EPS past 5Y-15.16% ROI-60.64% 52W High-57.96% Beta0.74
Dividend TTM- Quick Ratio5.75 Sales past 5Y73.25% Gross Margin-0.37% 52W Low22.84% ATR (14)0.84
Dividend Ex-Date- Current Ratio5.80 EPS Y/Y TTM-19.97% Oper. Margin-786.03% RSI (14)46.95 Volatility2.35% 7.79%
Employees270 Debt/Eq1.61 Sales Y/Y TTM- Profit Margin-757.52% Recom1.23 Target Price35.58
Option/ShortYes / Yes LT Debt/Eq1.54 EPS Q/Q-15.89% Payout- Rel Volume0.79 Prev Close10.62
Sales Surprise21.71% EPS Surprise21.75% Sales Q/Q- EarningsMay 05 AMC Avg Volume2.29M Price10.54
SMA200.15% SMA50-10.04% SMA200-31.53% Trades Volume1,808,473 Change-0.75%
Date Action Analyst Rating Change Price Target Change
Oct-24-24Initiated UBS Buy $37
Jun-28-24Initiated Jefferies Buy $37
Jan-31-24Downgrade Scotiabank Sector Outperform → Sector Perform $36 → $23
Dec-22-23Initiated Mizuho Buy $45
Oct-25-23Initiated BofA Securities Buy $29
Oct-11-23Initiated Goldman Buy $30
Jul-27-23Initiated Scotiabank Sector Outperform
Jul-11-23Initiated Guggenheim Buy $40
Apr-17-23Resumed BTIG Research Buy $34
Jan-31-23Initiated Stifel Buy $37
Show Previous Ratings
May-29-25 07:00AM
Syndax Announces Participation in June Investor Conferences
(GlobeNewswire)
May-14-25 09:30AM
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr)
(GlobeNewswire) -8.93%
May-12-25 04:01PM
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
(GlobeNewswire) -7.28%
May-09-25 09:55AM
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
(Zacks)
May-08-25 07:00AM
Syndax Announces Participation in May Investor Conferences
(GlobeNewswire) +10.21%
04:01PM Loading…
May-07-25 04:01PM
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
(GlobeNewswire) -6.11%
May-06-25 01:13PM
Q1 2025 Syndax Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents) -21.59%
03:06AM
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
May-05-25 05:10PM
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:08PM
Syndax: Q1 Earnings Snapshot
(Associated Press Finance)
04:01PM
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
(GlobeNewswire)
May-02-25 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(GlobeNewswire)
09:26AM
Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings
(GuruFocus.com)
Apr-28-25 07:00AM
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
(GlobeNewswire)
Apr-07-25 09:08AM
Syndax Pharmaceuticals: Down But Not Out
(Seeking Alpha)
04:05PM Loading…
Apr-04-25 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(GlobeNewswire) -9.71%
Apr-02-25 07:00AM
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
(GlobeNewswire) +7.99%
Mar-30-25 03:50AM
abrdn Life Sciences Investors Q4 2024 Commentary
(Seeking Alpha)
Mar-20-25 01:03PM
3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets
(SeekingAlpha) +7.47%
Mar-05-25 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(GlobeNewswire)
10:00AM
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...
(GuruFocus.com)
Mar-03-25 08:15AM
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
07:13AM
Syndax: Q4 Earnings Snapshot
(Associated Press Finance)
07:01AM
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
(GlobeNewswire)
Feb-28-25 07:07AM
Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result
(GuruFocus.com)
Feb-25-25 07:00AM
Syndax Announces Participation in March Investor Conferences
(GlobeNewswire)
Feb-24-25 07:00AM
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
(GlobeNewswire)
Feb-04-25 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Jan-30-25 07:00AM
Syndax Announces Participation in February Investor Conferences
(PR Newswire)
Jan-15-25 05:34PM
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
(PR Newswire)
07:00AM Loading…
Jan-13-25 07:00AM
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
(PR Newswire)
Jan-07-25 07:00AM
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
(PR Newswire)
Jan-03-25 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Dec-09-24 07:30AM
Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
(PR Newswire) -8.52%
Dec-07-24 06:15PM
Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
(PR Newswire)
Dec-04-24 01:32PM
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
(Insider Monkey)
Dec-03-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Nov-27-24 07:00AM
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
(PR Newswire)
Nov-18-24 07:12AM
Syndax secures FDA OK for new kind of leukemia drug
(BioPharma Dive)
06:39AM
FDA approves Syndaxs Revuforj to treat leukaemia
(Pharmaceutical Technology)
Nov-15-24 05:29PM
Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
(PR Newswire) -5.72%
Nov-14-24 08:00AM
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
(PR Newswire)
Nov-13-24 01:06PM
Syndaxs stock sinks by 25% despite AML trial meeting primary endpoint
(Pharmaceutical Technology)
07:21AM
Syndaxs revumenib meets primary results in AML trial
(TipRanks)
Nov-12-24 01:07PM
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
(Benzinga) -25.57%
07:00AM
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
(PR Newswire)
Nov-07-24 12:32AM
Q3 2024 Royalty Pharma PLC Earnings Call
(Thomson Reuters StreetEvents)
Nov-06-24 12:16PM
Q3 2024 Syndax Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents) +8.43%
05:00AM
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
(BioPharma Dive)
02:23AM
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
(GuruFocus.com)
Nov-05-24 05:10PM
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
04:09PM
Syndax: Q3 Earnings Snapshot
(Associated Press Finance)
04:01PM
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
(PR Newswire)
09:01AM
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
(PR Newswire)
09:00AM
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
(PR Newswire)
09:00AM
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
(PR Newswire)
04:32AM
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
(Pharmaceutical Technology)
Nov-04-24 04:15PM
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
(GlobeNewswire)
04:01PM
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo
(PR Newswire)
Nov-01-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
07:00AM
Syndax Announces Participation in November Investor Conferences
(PR Newswire)
Oct-29-24 07:00AM
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
(PR Newswire)
Oct-18-24 03:03PM
State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals
(GuruFocus.com)
Oct-09-24 03:54PM
Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
(GuruFocus.com)
Oct-04-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Sep-18-24 05:15PM
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
(PR Newswire)
Sep-06-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Sep-05-24 12:01AM
Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
(Insider Monkey)
Sep-02-24 05:22PM
10 Best Small-Cap Healthcare Stocks To Buy Now
(Insider Monkey)
Aug-15-24 12:32PM
FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo
(Pharmaceutical Technology)
10:11AM
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
(Benzinga)
Aug-14-24 05:34PM
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
(Business Wire)
Aug-12-24 07:00AM
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
(PR Newswire)
Aug-05-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire) -6.56%
Aug-01-24 04:46PM
Syndax: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
(PR Newswire)
08:00AM
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
(GlobeNewswire)
Jul-30-24 03:07PM
3 Biotech Stocks That Could Make Your Summer Unforgettable
(InvestorPlace)
Jul-29-24 02:42PM
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
(Investopedia) -10.21%
07:01AM
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
(PR Newswire)
Jul-25-24 09:55AM
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
(Zacks)
07:00AM
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
(PR Newswire)
Jul-09-24 09:55AM
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
(Zacks) +6.81%
Jul-05-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
Jun-17-24 09:00AM
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
(GlobeNewswire)
Jun-14-24 07:00AM
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
(PR Newswire)
Jun-10-24 07:30AM
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
(GlobeNewswire)
Jun-06-24 07:00AM
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
(PR Newswire)
Jun-05-24 07:00AM
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
(PR Newswire)
Jun-03-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
May-15-24 04:05PM
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
(PR Newswire)
May-12-24 08:26AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-09-24 07:00AM
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
(PR Newswire)
03:03AM
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
(GuruFocus.com)
May-08-24 09:22AM
Syndax Pharmaceuticals Q1 Net Loss Widens
(MT Newswires)
07:27AM
Syndax: Q1 Earnings Snapshot
(Associated Press Finance)
07:06AM
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
(PR Newswire)
May-03-24 04:05PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(PR Newswire)
May-01-24 07:00AM
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
(PR Newswire)
Apr-10-24 04:05PM
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
(PR Newswire)
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Botwood Nicholas A.J.Head of R&D, CMOMay 16 '25Buy8.9911,765105,82635,165May 19 04:03 PM
Huber Martin H. Jr.DirectorMay 19 '25Buy8.995,00044,95079,000May 19 04:02 PM
Katkin KeithDirectorMay 19 '25Buy9.1110,00091,120100,000May 19 04:01 PM
Metzger Michael AChief Executive OfficerMar 14 '25Option Exercise7.206,07443,733306,195Mar 17 06:01 AM
Metzger Michael AChief Executive OfficerMar 04 '25Option Exercise7.207,81456,261307,935Mar 06 04:10 PM
Metzger Michael AChief Executive OfficerMar 04 '25Sale15.057,814117,564300,121Mar 06 04:10 PM
MICHAEL METZGEROfficerMar 04 '25Proposed Sale15.4813,888214,986Mar 04 05:10 PM
Goldan Keith A.Chief Financial OfficerFeb 10 '25Sale15.503,77758,55990,746Feb 12 05:16 PM
Metzger Michael AChief Executive OfficerFeb 10 '25Sale15.5013,288206,017300,121Feb 12 05:15 PM
Gallagher NeilPresident, Head of R&DFeb 10 '25Sale15.504,61871,59785,095Feb 12 05:13 PM
Goldan Keith A.OfficerFeb 10 '25Proposed Sale15.503,77758,559Feb 10 03:29 PM
Metzger Michael AOfficerFeb 10 '25Proposed Sale15.5013,288206,017Feb 10 03:20 PM
Gallagher NeilOfficerFeb 10 '25Proposed Sale15.504,61871,597Feb 10 03:17 PM
Goldan Keith A.Chief Financial OfficerJun 14 '24Buy20.031,25025,03752,623Jun 17 09:26 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.